Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough

Cancer Communications

Table 2 Published or presented studies with results in NSCLC patients treated with targeted agents beyond EGFR-TKIs

Target	Agent	Phase	Eligibility	Number of patients	ORR (%)	PFS (months)	OS (months)	References
ALK	Crizotinib	III	Pretreated, ALK-rearranged	347	65	7.7	20.3	[53]
	Crizotinib	III	Untreated, ALK-rearranged	343	74	10.9	NR	[54]
	Ceritinib	I	Pretreated, ALK-rearranged	114 (at least 400 mg)	58 (overall population)	7.0	NR	[56]
					56 (crizotinib-treated)	6.9
					62 (crizotinib-naive)	10.4
	Alectinib	I–II	ALK-rearranged	46	93.5	NR	NR	[58]
	Alectinib	I–II	ALK inhibitor-naive	46	93.5	NR	NR	[58]
	Alectinib	I–II	ALK-rearranged, crizotinib-resistant	47	55	NR	NR	[60]
ROS1	Crizotinib	I	ROS1-rearranged	50	72	19.2	NR	[61]
MET	Crizotinib	I	MET-amplified	13	20 (intermediate amplification)	NR	NR	[62]
MET	Crizotinib	I	MET-amplified	13	50 (high amplification)	NR	NR	[62]
BRAF	Dabrafenib	II	BRAF ^V600E mutation-positive	17	54	NR	NR	[63]
HER2	Anti-HER2 agents	Retrospective	HER2 mutation-positive	16	50	5.1	NR	[64]
FGFR1	BGJ398	I	FGFR1-amplified	17	11.7	NR	NR	[65]

ALK anaplastic lymphoma kinase, ROS1 c-ros oncogene 1, MET proto-oncogene protein c-met, BRAF v-Raf murine sarcoma viral oncogene homolog B1, HER2 human epidermal growth factor receptor 2, FGFR1 fibroblast growth factor receptor 1, ORR objective response rate, NR not reported or not reached. Other abbreviations as in Table 1.

ISSN: 2523-3548